Research Progress in Treatment of Chronic Lymphocytic Leukemia --Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1910-1915, 2023.
Article
en Zh
| WPRIM
| ID: wpr-1010059
Biblioteca responsable:
WPRO
ABSTRACT
Chronic lymphocytic leukemia (CLL) is a low-grade lymphoproliferative tumor that occurs frequently in middle-aged and elderly people. Early and precise intervention can effectively improve the clinical prognosis of CLL patients. In the past, chemotherapy was the main treatment plan. With the development of molecular biology and the continuous advent of immune targeting drugs, targeted drugs targeting B cell receptor signaling pathway have shown high clinical application value in the diagnosis and treatment path of CLL. Cellular immunotherapies such as CAR-T also offer hope for patients with relapsed and refractory CLL. Allogeneic hematopoietic stem cell transplantation and multi-drug combination have also shown remarkable results in clinical practice. The purpose of this article is to review the latest research progress in the treatment of CLL.
Palabras clave
Texto completo:
1
Banco de datos:
WPRIM
Asunto principal:
Leucemia Linfocítica Crónica de Células B
/
Transducción de Señal
/
Trasplante de Células Madre Hematopoyéticas
/
Inmunoterapia
Límite:
Humans
Idioma:
Zh
Año:
2023
Tipo del documento:
Article